123 related articles for article (PubMed ID: 8438414)
1. Suppression of OKT3-induced tumor necrosis factor alpha formation by pentoxifylline in renal transplant recipients.
Leimenstoll G; Zabel P; Schroeder P; Schlaak M; Niedermayer W
Transplant Proc; 1993 Feb; 25(1 Pt 1):561-3. PubMed ID: 8438414
[No Abstract] [Full Text] [Related]
2. Pentoxifylline reduces the first-dose reactions following OKT3.
Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
[No Abstract] [Full Text] [Related]
3. The effects of oral pentoxifylline on the cytokine release syndrome during inductive OKT3.
DeVault GA; Kohan DE; Nelson EW; Holman JM
Transplantation; 1994 Feb; 57(4):532-40. PubMed ID: 8116037
[TBL] [Abstract][Full Text] [Related]
4. Activation of coagulation and fibrinolysis during treatment with OKT3.
ten Berge RJ; Raasveld MH; van Diepen FN; Hack CE
Transplant Proc; 1993 Feb; 25(1 Pt 1):566-7. PubMed ID: 8438416
[No Abstract] [Full Text] [Related]
5. Comparison of T10Bg.1A-31 and OKT3 in treating acute renal allograft rejection.
Lucas BA; Waid TH; Thompson JS; Brown SA; Munch LC; McKeown JW; Kryscio RJ; Prebeck RJ
Transplant Proc; 1993 Feb; 25(1 Pt 1):543-5. PubMed ID: 8438406
[No Abstract] [Full Text] [Related]
6. Morbidity of intraoperative OKT3 administration in primary cadaveric renal transplant recipients.
Kupin W; Venkat KK; Ikemiyashiro D; Ocdol H; Mozes M; Anaise D; Johnson C
Transplant Proc; 1993 Feb; 25(1 Pt 1):572-4. PubMed ID: 8438419
[No Abstract] [Full Text] [Related]
7. Tumor necrosis factor and interleukin-6 in cerebrospinal fluid of a patient with recurrent adverse central nervous system events following OKT3.
Agarwal RK; Ostaszewski ML; Feld LG; Springate JE; Moxey-Mims MM; O'Neil KM
Transplant Proc; 1993 Apr; 25(2):2143-4. PubMed ID: 8470295
[No Abstract] [Full Text] [Related]
8. Soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor plasma levels in renal allograft recipients.
Noronha IL; Daniel V; Rambausek M; Waldherr R; Opelz G
Transplant Proc; 1990 Aug; 22(4):1859-60. PubMed ID: 2117814
[No Abstract] [Full Text] [Related]
9. Role of maintenance immunosuppression and methylprednisolone in OKT3-induced cytokine release.
Peces R; Urra JM; Gorostidi M; López-Larrea C
Transplant Proc; 1992 Dec; 24(6):2596-9. PubMed ID: 1465877
[No Abstract] [Full Text] [Related]
10. Prophylactic OKT3: practical considerations for the prevention of first-dose reactions.
Doutrelepont JM; Abramowicz D; Borre B; Lemoine A; De Pauw L; Kinnaert P; Vereerstraeten P; Vanherweghem JL; Goldman M
Transplant Proc; 1993 Apr; 25(2 Suppl 1):45-6. PubMed ID: 8465424
[No Abstract] [Full Text] [Related]
11. Immunological follow-up of renal allograft recipients treated with the BMA 031 (anti-TCR) monoclonal antibody.
Chatenoud L; Ferran C; Legendre C; Kurrle R; Kreis H; Bach JF
Transplant Proc; 1990 Aug; 22(4):1787-8. PubMed ID: 2117809
[No Abstract] [Full Text] [Related]
12. Complications of using OKT3 for induction of immunosuppression in recipients of kidneys from nonheart beating donors.
Kehinde EO; Veitch PS; Scriven SD; Varty K; Morgan JD; Furness P; Horsburgh T; Feehally J; Bell PR
Transplant Proc; 1994 Dec; 26(6):3123-5. PubMed ID: 7998090
[No Abstract] [Full Text] [Related]
13. Pentoxifylline does not prevent the cytokine-induced first dose reaction following OKT3--a randomized, double-blind placebo-controlled study.
Vincenti F; Danovitch GM; Neylan JF; Steiner RW; Everson MP; Gaston RS
Transplantation; 1996 Feb; 61(4):573-7. PubMed ID: 8610383
[TBL] [Abstract][Full Text] [Related]
14. Effect of oral pentoxyfylline on the OKT3-induced cytokine-release syndrome among renal allograft recipients.
Vasquez EM; Pollak R
Clin Transplant; 1996 Jun; 10(3):294-7. PubMed ID: 8826669
[TBL] [Abstract][Full Text] [Related]
15. Encephalopathy following the use of OKT3 in renal allograft transplantation.
Shihab FS; Barry JM; Norman DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):31-4. PubMed ID: 8465419
[No Abstract] [Full Text] [Related]
16. Cytokine secretion capacity of mononuclear cells in renal transplant recipients: the effect of two different dose schedules.
Leimenstoll G; Engemann R; Gassel J; Hoffmann S; Preusse D; Schlag H; Niedermayer W
Transplant Proc; 1993 Aug; 25(4):2666-8. PubMed ID: 8356715
[No Abstract] [Full Text] [Related]
17. Regional cytokine changes following OKT3 induction for islet cell transplantation in humans: early increase in portal and systemic levels of interleukin-6 and tumor necrosis factors.
Burke GW; Alejandro R; Cirocco R; Nery J; Mintz D; Miller J
Transplant Proc; 1992 Jun; 24(3):962-4. PubMed ID: 1604687
[No Abstract] [Full Text] [Related]
18. A pilot trial of recombinant human interleukin-10 in kidney transplant recipients receiving OKT3 induction therapy.
Wissing KM; Morelon E; Legendre C; De Pauw L; LeBeaut A; Grint P; Maniscalki M; Ickx B; Vereerstraeten P; Chatenoud L; Kreis H; Goldman M; Abramowicz D
Transplantation; 1997 Oct; 64(7):999-1006. PubMed ID: 9381549
[TBL] [Abstract][Full Text] [Related]
19. Induction of an acute phase response after OKT3 therapy.
Pohanka E; Kovarik J; Klauser R; Woloszcsuk W; Zlabinger GJ
Transplant Proc; 1992 Feb; 24(1):269-70. PubMed ID: 1371618
[No Abstract] [Full Text] [Related]
20. Reduction of the initial febrile response to OKT3 with indomethacin.
First MR; Schroeder TJ; Hariharan S; Weiskittel P
Transplant Proc; 1993 Apr; 25(2 Suppl 1):52-4. PubMed ID: 8465426
[No Abstract] [Full Text] [Related]
[Next] [New Search]
